All In MedTech

FDA Clearance Tracker · P160046-S010

VENTANA PD-L1 (SP263) Assay

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Oct 15, 2021 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Oct 15, 2021

Approved

Time to decision

123 days

Received Jun 14, 2021. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P160046-S010
Device name
VENTANA PD-L1 (SP263) Assay
Applicant location
Tucson, AZ
Received
Jun 14, 2021
Decided
Oct 15, 2021
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P160046

Device type

Device class
Class III

Every decision under product code PLS

FDA's approval statement

As written in FDA's record.

Approval for the VENTANA PD-L1 (SP263) Assay as a CDx for identifying patients with NSCLC tumors with PD-L1 status of >= 1% TC who may benefit from treatment with TECENTRIQ.

Source documents

Other decisions for Ventana Medical Systems, Inc.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.